Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Panacea Biotec has informed that Shantanu Yeshwant Nalavadi has been appointed as an Additional Director of the Company (in the capacity of Non-Executive Director) with effect from December 10, 2019. He is not related to any Director of the Company. Brief profile of Shantanu Yeshwant Nalavadi is enclosed herewith as Annexure - A. In accordance with the circular dated June 20, 2018, issued by the Stock Exchanges, it has got the confirmation from Shantanu Yeshwant Nalavadi that he is not debarred from accessing the capital market and / or restrained from holding the office of Director by virtue of any SEBI Order or any other such authority. Further, Nithin Krishna Kaimal, Non-Executive Director of the Company, has resigned from the directorship of the Company with effect from December 10, 2019.
The above information is a part of company’s filings submitted to BSE.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1675.20 |
| Dr. Reddys Lab | 1235.40 |
| Cipla | 1238.30 |
| Zydus Lifesciences | 942.55 |
| Lupin | 2324.25 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: